The new facility is a purpose-built laboratory dedicated to small and large molecule bioanalysis, flow cytometry, biomarkers, and biodistribution.
According to the contract research organization (CRO), the expansion is “an integral part” of its strategic plan to grow in the global laboratory services market and follows an increasing demand for bioanalysis and biomarker services.
The company will relocate some of its laboratory operations to the new building, which Jean-François Le Bigot, chairman and CEO of CiToxLAB Group said will free up space in the main building, allowing it to increase its animal room capacity.
Andrew Graham, site manager at CiToxLAB North America, added: “The new building we have just purchased will allow us to better meet the increasing needs of our clients for a one-stop-shop CRO in laboratory sciences investigations.”
Last November, CiToxLAB acquired AccelLAB, a preclinical medical device CRO to expand its services portfolio to medical devices.